Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Literature DB >> 29610746

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Emilie Mamessier^1,2, David J Birnbaum^1,2,3, Pascal Finetti^1,2, Daniel Birnbaum^1,2, François Bertucci^1,2,4.

Abstract

Entities: Disease Gene

Year: 2018 PMID： 29610746 PMCID： PMC5879522 DOI： 10.21037/atm.2017.11.26

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

30 in total

Review 1. The future of immune checkpoint therapy.

Authors: Padmanee Sharma; James P Allison
Journal: Science Date: 2015-04-03 Impact factor: 47.728

Review 2. Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors: Leonidas C Platanias
Journal: Nat Rev Immunol Date: 2005-05 Impact factor: 53.106

3. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).

Authors: Seung-Jin Lee; Byeong-Churl Jang; Soo-Woong Lee; Young-Il Yang; Seong-Il Suh; Yeong-Min Park; Sangtaek Oh; Jae-Gook Shin; Sheng Yao; Lieping Chen; In-Hak Choi
Journal: FEBS Lett Date: 2006-01-09 Impact factor: 4.124

Review 4. The blockade of immune checkpoints in cancer immunotherapy.

Authors: Drew M Pardoll
Journal: Nat Rev Cancer Date: 2012-03-22 Impact factor: 60.716

5. Deubiquitination and Stabilization of PD-L1 by CSN5.

Authors: Seung-Oe Lim; Chia-Wei Li; Weiya Xia; Jong-Ho Cha; Li-Chuan Chan; Yun Wu; Shih-Shin Chang; Wan-Chi Lin; Jung-Mao Hsu; Yi-Hsin Hsu; Taewan Kim; Wei-Chao Chang; Jennifer L Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Yi Yang; Chung-Hsuan Chen; Aysegul A Sahin; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal: Cancer Cell Date: 2016-11-17 Impact factor: 31.743

6. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.

Authors: Jin Peng; Junzo Hamanishi; Noriomi Matsumura; Kaoru Abiko; Kumuruz Murat; Tsukasa Baba; Ken Yamaguchi; Naoki Horikawa; Yuko Hosoe; Susan K Murphy; Ikuo Konishi; Masaki Mandai
Journal: Cancer Res Date: 2015-11-16 Impact factor: 12.701

7. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors: Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal: Nature Date: 2017-08-16 Impact factor: 49.962

Review 8. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.

Authors: Alexander Eggermont; Caroline Robert; Jean Charles Soria; Laurence Zitvogel
Journal: Oncoimmunology Date: 2014-01-03 Impact factor: 8.110

9. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors: Y Ishida; Y Agata; K Shibahara; T Honjo
Journal: EMBO J Date: 1992-11 Impact factor: 11.598

10. NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment.

Authors: Gang Huang; Qianjun Wen; Yongliang Zhao; Qiangguo Gao; Yun Bai
Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240

22 in total

1. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.

Authors: Young Wha Koh; Jae-Ho Han; Seokjin Haam; Joonho Jung; Hyun Woo Lee
Journal: Oncoimmunology Date: 2019-06-14 Impact factor: 8.110

2. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

Authors: Emilien Billon; Pascal Finetti; Alexandre Bertucci; Patricia Niccoli; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal: Oncoimmunology Date: 2019-08-28 Impact factor: 8.110

3. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

Authors: Jon Zugazagoitia; Yuting Liu; Maria Toki; John McGuire; Fahad Shabbir Ahmed; Brian S Henick; Richa Gupta; Scott N Gettinger; Roy S Herbst; Kurt A Schalper; David L Rimm
Journal: J Thorac Oncol Date: 2019-10-09 Impact factor: 15.609

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Review 1. The future of immune checkpoint therapy.

Review 2. Mechanisms of type-I- and type-II-interferon-mediated signalling.

3. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).

Review 4. The blockade of immune checkpoints in cancer immunotherapy.

5. Deubiquitination and Stabilization of PD-L1 by CSN5.

6. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.

7. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Review 8. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.

9. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

10. NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment.

1. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.

2. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

3. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

4. Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer.

5. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.

Review 6. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.

Review 7. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value.

8. A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment.

Review 9. Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.

Review 10. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.